Menu Back to Global-Pharmacovigilance-and-Risk-Management-Strategies-Conference


February 6-8, 2023

DIA's Global Pharmacovigilance and Risk Management Strategies Conference was developed by recognized experts from the biopharmaceutical industry and global regulatory agencies. This conference provides the background, context, and opportunities to discuss current challenges alongside fresh problem-solving strategies that matter most to professionals working in the field.

While we develop our 2023 Agenda, please take a look at the 2022 final agenda.

Program Committee

  • Jeremy  Jokinen, PhD, MS
    Jeremy Jokinen, PhD, MS Vice President and Head, Global Risk Management & International Patient Safety
    Bristol-Myers Squibb Company, United States
  • Annette S. Williams, MBA, RPh
    Annette S. Williams, MBA, RPh Vice President, Pharmacovigilance
    IQVIA, United States
  • James  Buchanan, PharmD
    James Buchanan, PharmD President
    Covilance LLC, United States
  • Barbara  Hendrickson, MD
    Barbara Hendrickson, MD Immunology Therapeutic Area Head, Pharmacovigilance and Patient Safety
    AbbVie, Inc., United States
  • Mamiko  Kasho
    Mamiko Kasho Executive Director, Global PV Management Dept., Global Safety HQs
    Eisai Co., Ltd., Japan
  • Susan  Kindig, JD, MD
    Susan Kindig, JD, MD Executive Director, Medical & Drug Safety
    Halozyme, United States
  • Jamie Ridley Klucken, PharmD, MBA, RPh
    Jamie Ridley Klucken, PharmD, MBA, RPh Safety Evaluator, Division of Pharmacovigilance, OSE, CDER
    FDA, United States
  • Mengchun  Li, MD, MPA
    Mengchun Li, MD, MPA Director, Phamacovigilance
    Global Alliance For TB Drug Development, United States
  • Sarah  Vaughan
    Sarah Vaughan Head of Vigilance Development
    Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
  • Jo  Wyeth, PharmD
    Jo Wyeth, PharmD Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
    FDA, United States
Load More